Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_3
3
60%

Phase Distribution

2

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 33 (60.0%)

Trials by Status

completed240%
terminated360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

NCT01940887
terminatedphase_3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01944839
terminatedphase_3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01940900
completedphase_1

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

NCT00569140
completedphase_1

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

NCT02859441

Clinical Trials (5)

Showing 5 of 5 trials
NCT01940887Phase 3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Terminated
NCT01944839Phase 3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Terminated
NCT01940900Phase 3

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Terminated
NCT00569140Phase 1

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Completed
NCT02859441Phase 1

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5